These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22355641)

  • 1. Polymeric human Fc-fusion proteins with modified effector functions.
    Mekhaiel DN; Czajkowsky DM; Andersen JT; Shi J; El-Faham M; Doenhoff M; McIntosh RS; Sandlie I; He J; Hu J; Shao Z; Pleass RJ
    Sci Rep; 2011; 1():124. PubMed ID: 22355641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-engineered antibodies with immune effector functions completely abolished.
    Wilkinson I; Anderson S; Fry J; Julien LA; Neville D; Qureshi O; Watts G; Hale G
    PLoS One; 2021; 16(12):e0260954. PubMed ID: 34932587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
    Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ
    J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity.
    Lagassé HAD; Hengel H; Golding B; Sauna ZE
    AAPS J; 2019 May; 21(4):62. PubMed ID: 31062128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
    Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
    MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
    Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
    Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
    Dumont JA; Low SC; Peters RT; Bitonti AJ
    BioDrugs; 2006; 20(3):151-60. PubMed ID: 16724863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.
    Wilkinson IC; Fowler SB; Machiesky L; Miller K; Hayes DB; Adib M; Her C; Borrok MJ; Tsui P; Burrell M; Corkill DJ; Witt S; Lowe DC; Webster CI
    MAbs; 2013; 5(3):406-17. PubMed ID: 23567207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified recombinant human IgG1-Fc is superior to natural intravenous immunoglobulin at inhibiting immune-mediated demyelination.
    Baksmeier C; Blundell P; Steckel J; Schultz V; Gu Q; Da Silva Filipe A; Kohl A; Linnington C; Lu D; Dell A; Haslam S; Wang J; Czajkowsky D; Goebels N; Pleass RJ
    Immunology; 2021 Sep; 164(1):90-105. PubMed ID: 33880776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.
    Patel DA; Puig-Canto A; Challa DK; Perez Montoyo H; Ober RJ; Ward ES
    J Immunol; 2011 Jul; 187(2):1015-22. PubMed ID: 21690327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
    Liang Y; Qiu H; Glinka Y; Lazarus AH; Ni H; Prud'homme GJ; Wang Q
    J Gene Med; 2011 Sep; 13(9):470-7. PubMed ID: 21786368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative methods for developing Fc mutants with extended half-lives.
    Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
    Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.
    Bitonti AJ; Dumont JA; Low SC; Peters RT; Kropp KE; Palombella VJ; Stattel JM; Lu Y; Tan CA; Song JJ; Garcia AM; Simister NE; Spiekermann GM; Lencer WI; Blumberg RS
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9763-8. PubMed ID: 15210944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.
    Goebl NA; Babbey CM; Datta-Mannan A; Witcher DR; Wroblewski VJ; Dunn KW
    Mol Biol Cell; 2008 Dec; 19(12):5490-505. PubMed ID: 18843053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.
    Fitzpatrick EA; Wang J; Strome SE
    Front Immunol; 2020; 11():496. PubMed ID: 32269572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.